Nanocomposite Imaging System for the Eye

纳米复合眼部成像系统

• 批准号: 8060879
• 负责人: Paul K. Olson
• 金额: $ 27.35万
• 依托单位: KYPHA, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8060879
• 关键词: 3-Dimensional; Accounting; Acoustics; Acute; Adverse effects; Affect; Age related macular degeneration; Alkanes; American; Aqueous Humor; Biodistribution; Biological Markers; Biological Products; Blindness; Blood Vessels; Cells; Clinic; Clinical Trials; Complement; Complement 3d Receptors; Complement Inactivators; Contrast Media; Deposition; Diagnosis; Disease; Early Diagnosis; Effectiveness; Equipment; Experimental Animal Model; Eye; Frequencies; Gases; Goals; Home environment; Homing; Image; Imaging Techniques; Imaging technology; Impairment; Incidence; Inflammation; Inflammatory; Legal Blindness; Ligands; Location; Marketing; Measures; Methods; Modality; Modeling; Monitor; Optic Nerve; Optics; Patient Monitoring; Patients; Persons; Pharmacologic Substance; Rattus; Recurrence; Retina; Retinal; Retinal Diseases; Severities; Site; Small Business Innovation Research Grant; Specialist; System; Technology; Testing; Therapeutic; Time; Tissues; Toxicology; Ultrasonography; United States; Universities; Uvea; Uveitis; Vascular Endothelial Cell; Vision; Vitreous humor; anterior chamber; base; design; disorder control; improved; in vitro testing; nanocomposite; optical imaging; prevent; response; tool

DESCRIPTION (provided by applicant): The purpose of this SBIR project is to develop a new dual-modality inflammation imaging technology to early detect Uveitis, an ocular inflammation-related disorder. This technology, based on nanocomposites (NCs) that function as dual-modality fluorescent and acoustic contrast agents for optical and ultrasound imaging techniques, will allow both quantitative and whole-eye inflammation monitoring. In addition, the contrast-enhanced ultrasound (CEUS) modality means the NCs can be monitored using equipment present in most retinal specialists' offices. In United States, Uveitis affects 350,000 persons and is the fourth leading cause of blindness responsible for 30,000 new cases each year. The loss of vision is correlated with the severity, recurrence and duration of inflammatory episodes. Hence, early detection and continued control of the disease are critical. For treating uveitis, it is desirable to have a method that can quantitatively measure the extent of inflammation in the entire eye. This would aid in both assessing the extent of inflammation in monitoring the patients response to treatment. Current methods for monitoring ocular inflammation lack either the ability to (i) assess the whole eye or (ii) not quantitative. At present, no single technology can provide both quantitative and whole- eye monitoring of Uveitis-related inflammation. The new concurrent optical and ultrasound imaging that we propose will quickly, quantitatively and non- invasively assess inflammation in the entire eye. The first aim is to produce acoustically and fluorescently active NCs. In order to precisely locate and quantify ocular inflammation and allow more accurate monitoring of the patient response to Uveitis treatment, NCs will be decorated with ligands that target key biomarkers up- regulated on activated vascular endothelial cells. This strategy will not only improve diagnosis of inflammation, but also the degree of inflammation. The successful completion of this technology would produce a paradigm-shifting advance in how retinal specialists will easily and rapidly diagnose Uveitis while simultaneously monitoring the location and extent of the associated ocular inflammation. Specialists will be able to implement a therapeutic strategy early and then monitor and adjust over time as fluctuations in inflammation and potential side-effects present, thus preventing vision impairments. PUBLIC HEALTH RELEVANCE: The aim of the proposal is to develop a new dual-modality inflammation imaging technology to early detect uveitis, an ocular inflammation-related disorder. Uveitis affects 350,000 persons and is the fourth leading cause of blindness responsible for 30,000 new cases each year. The successful completion of this technology would produce a paradigm-shifting advance in how retinal specialists will easily and rapidly diagnose uveitis while simultaneously monitoring the location and extent of the associated ocular inflammation, thus allowing them to implement an optimal therapy.

描述（由申请人提供）： 该 SBIR 项目的目的是开发一种新的双模态炎症成像技术，以早期检测葡萄膜炎（一种眼部炎症相关疾病）。该技术基于纳米复合材料（NC），作为光学和超声成像技术的双模态荧光和声学对比剂，将允许定量和全眼炎症监测。此外，对比增强超声 (CEUS) 模式意味着可以使用大多数视网膜专家办公室现有的设备来监测 NC。在美国，葡萄膜炎影响 350,000 人，是导致失明的第四大原因，每年新增 30,000 例病例。视力丧失与炎症发作的严重程度、复发和持续时间相关。因此，早期发现和持续控制该疾病至关重要。为了治疗葡萄膜炎，需要一种能够定量测量整个眼睛炎症程度的方法。这将有助于评估炎症程度以及监测患者对治疗的反应。目前监测眼部炎症的方法缺乏（i）评估整个眼睛的能力或（ii）无法定量的能力。目前，没有一种技术可以同时提供葡萄膜炎相关炎症的定量和全眼监测。我们提出的新的并行光学和超声成像将快速、定量和非侵入性地评估整个眼睛的炎症。第一个目标是生产具有声学和荧光活性的NC。为了精确定位和量化眼部炎症，并更准确地监测患者对葡萄膜炎治疗的反应，NC 将用针对活化血管内皮细胞上调的关键生物标志物的配体进行装饰。这种策略不仅可以改善炎症的诊断，还可以改善炎症的程度。这项技术的成功完成将为视网膜专家如何轻松快速地诊断葡萄膜炎，同时监测相关眼部炎症的位置和程度带来范式转变的进步。专家将能够尽早实施治疗策略，然后随着炎症波动和潜在副作用的出现进行监测和调整，从而防止视力障碍。 公共卫生相关性： 该提案的目的是开发一种新的双模态炎症成像技术，以早期检测葡萄膜炎（一种眼部炎症相关疾病）。葡萄膜炎影响 350,000 人，是导致失明的第四大原因，每年新增 30,000 例病例。这项技术的成功完成将在视网膜专家如何轻松快速地诊断葡萄膜炎同时监测相关眼部炎症的位置和程度方面产生范式转变的进步，从而使他们能够实施最佳治疗。